Vertex Pharmaceuticals up after raising 2026 revenue forecast
** Shares of Vertex Pharmaceuticals VRTX.O rise 2.1% to $565 in extended trading
** Co raises its annual revenue forecast to between $13.15 billion and $13.25 billion, from $13.1 billion to $13.2 billion previously
** Posts Q3 revenue of $3.44 billion compared with analysts' estimates of $3.42 billion, according to data compiled by LSEG
** Reports Q3 adj. profit per share of $4.76 versus average estimate of $4.79
** BMO says a clean quarter clears the path to the FDA's November 30 decision on Vertex's povetacicept for IgA nephropathy
** As of last close, stock up 22% YTD